These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 16686808)
41. Barriers to patient-physician communication about out-of-pocket costs. Alexander GC; Casalino LP; Tseng CW; McFadden D; Meltzer DO J Gen Intern Med; 2004 Aug; 19(8):856-60. PubMed ID: 15242471 [TBL] [Abstract][Full Text] [Related]
42. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans. Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257 [TBL] [Abstract][Full Text] [Related]
43. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013. Brouwer ED; Basu A; Yeung K Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747 [TBL] [Abstract][Full Text] [Related]
44. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries. Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672 [TBL] [Abstract][Full Text] [Related]
45. What is in your wallet? A cluster randomized trial of the effects of showing comparative patient out-of-pocket costs on primary care prescribing for uncomplicated hypertension. Tamblyn R; Winslade N; Qian CJ; Moraga T; Huang A Implement Sci; 2018 Jan; 13(1):7. PubMed ID: 29321043 [TBL] [Abstract][Full Text] [Related]
46. Communication with Physicians about Health Care Costs: Survey of an Insured Population. Henrikson NB; Chang E; Ulrich K; King D; Anderson ML Perm J; 2017; 21():16-070. PubMed ID: 28406786 [TBL] [Abstract][Full Text] [Related]
47. Perverse incentives in the Medicare prescription drug benefit. McAdams D; Schwarz M Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042 [TBL] [Abstract][Full Text] [Related]
48. Out-of-pocket pharmacy expenditures for veterans under medicare part D. Rupper RW; Bair BD; Sauer BC; Nebeker JR; Shinogle J; Samore M Med Care; 2007 Oct; 45(10 Supl 2):S77-80. PubMed ID: 17909387 [TBL] [Abstract][Full Text] [Related]
49. Experts' agency problems: evidence from the prescription drug market in Japan. Iizuka T Rand J Econ; 2007; 38(3):844-62. PubMed ID: 18478669 [TBL] [Abstract][Full Text] [Related]
50. U.S. Internists' Perspectives on Discussing Cost of Care With Patients: Structured Interviews and a Survey. Perez SL; Weissman A; Read S; Smith CD; Colello L; Peter D; Nickel W Ann Intern Med; 2019 May; 170(9_Suppl):S39-S45. PubMed ID: 31060057 [TBL] [Abstract][Full Text] [Related]
51. Formulary tiers, medication cost sharing, and transparency in bronze and silver qualified health plans in 2014 vs 2018. Hung A; Sauvageau G J Manag Care Spec Pharm; 2021 Oct; 27(10):1332-1340. PubMed ID: 34595951 [No Abstract] [Full Text] [Related]
52. Consumer Cost-Sharing in Marketplace vs. Employer Health Insurance Plans, 2015. Gabel J; Whitmore H; Green M; Stromberg S; Oran R Issue Brief (Commonw Fund); 2015 Dec; 38():1-11. PubMed ID: 26761957 [TBL] [Abstract][Full Text] [Related]
53. Giving formulary and drug cost information to providers and impact on medication cost and use: a longitudinal non-randomized study. Tseng CW; Lin GA; Davis J; Taira DA; Yazdany J; He Q; Chen R; Imamura A; Dudley RA BMC Health Serv Res; 2016 Sep; 16(1):499. PubMed ID: 27654857 [TBL] [Abstract][Full Text] [Related]
54. General practitioners' views on the influence of cost on the prescribing of asthma preventer medicines: a qualitative study. Tudball J; Reddel HK; Laba TL; Jan S; Flynn A; Goldman M; Lembke K; Roughead E; Marks GB; Zwar N Aust Health Rev; 2019 Jul; 43(3):246-253. PubMed ID: 29754592 [TBL] [Abstract][Full Text] [Related]
55. Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use. Shrank WH; Stedman M; Ettner SL; DeLapp D; Dirstine J; Brookhart MA; Fischer MA; Avorn J; Asch SM J Gen Intern Med; 2007 Sep; 22(9):1298-304. PubMed ID: 17647066 [TBL] [Abstract][Full Text] [Related]
56. Data watch. Is this the way to manage pharmacy costs? Bus Health; 1997 Sep; 15(9):94. PubMed ID: 10173238 [No Abstract] [Full Text] [Related]
57. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Gurwitz JH; McLaughlin TJ; Fish LS Health Serv Res; 1995 Dec; 30(5):672-85. PubMed ID: 8537226 [TBL] [Abstract][Full Text] [Related]
58. Drug plan design incentives among Medicare prescription drug plans. Huskamp HA; Keating NL; Dalton JB; Chernew ME; Newhouse JP Am J Manag Care; 2014 Jul; 20(7):562. PubMed ID: 25295402 [TBL] [Abstract][Full Text] [Related]
59. Patient-physician discussions about costs: definitions and impact on cost conversation incidence estimates. Hunter WG; Hesson A; Davis JK; Kirby C; Williamson LD; Barnett JA; Ubel PA BMC Health Serv Res; 2016 Mar; 16():108. PubMed ID: 27036177 [TBL] [Abstract][Full Text] [Related]
60. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). Karter AJ; Parker MM; Solomon MD; Lyles CR; Adams AS; Moffet HH; Reed ME Health Serv Res; 2018 Apr; 53(2):1227-1247. PubMed ID: 28474736 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]